A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
Top Ten U.S. Drugs (by sales) Losing Patent Exclusivity in 2021
- Lucentis (Genentech/Roche) 2020 $1.6 Billion in sales
- Bystolic (AbbVie/Allergan) 2020 $600 Million in sales
- Vascepa (Amarin) 2020 $598 Million in sales
- Nothera (Lundbeck) 2020 $416 Million in sales
- Narcan (Emergent Biosolutions) 2020 $311 Million in sales
- Brovana (Sunovion) 2020 $275 Million in sales
- Sutent (Pfizer) 2020 $223 Million in sales
- Saphris (AbbVie/Allergan) 2020 $217 Million in sales
- Amitiza (Mallinckrodt) 2020 $180 Million in sales
- Feraheme (Amag Pharma) 2020 $150 Million in sales
Source: JDSupra, April 29, 2021 - https://www.jdsupra.com/legalnews/top-drugs-losing-patent-exclusivity-in-794925…
ACO Performance Case Studies
*By signing up for this offer you agree to receive the Accountable Care bulletin and the HealthExecWire news release bulletin.
Accountable Care
Offerings
Value-Based Payments
Offerings
Analytics
Offerings
Population Health
Offerings
Payers & Providers
Offerings